Strategies That Make a Difference

Our Team

Randy J. Koslo, PhD

Medical Affairs, Clinical and Innovation Strategies

Randy Koslo is a respected R&D leader with over 25 years experience identifying and implementing innovation strategies for OTC drugs, dietary supplements, medical devices, Rx-to-OTC switch and Rx drugs.

In eleven years at GSK Consumer Healthcare, Randy led R&D innovation for a broad range of new growth categories and established franchises. Specifically:

  • Randy served as Global VP R&D for Respiratory Health where he collaborated with Marketing to develop the franchise growth vision, new product pipeline, regulatory strategy, and global expansion plan for established and emerging markets. Key accomplishments included: the global Flonase® switch strategy; sensory innovations for the Beechams® Cold & Flu business in Europe; introduction, expansion, and patent defense of Breathe Right® in China; brand extensions in Central and Eastern Europe including Russia; and a range of Panadol® Cold & Flu innovations in Australia.
  • As VP R&D for the GSK’s Venture Group, he led the process that resulted in clinical innovation, technical advances in drugs, devices and medical foods, and selection of 4 new categories for global strategic growth through Rx-to-OTC switch,
  • As Director Medical Affairs for North America New Opportunities, Randy supported innovation for all Rx dermatology brands including Cutivate™, established OTC brand franchises, and current and future Rx-to-OTC switch products.

Before joining GSK, Randy served as Director of Medical Affairs & Clinical Research at Bayer Consumer Care, where he was responsible for all clinical operations, medical affairs, biostatistics, clinical drug supplies and drug safety for North America as well as global new business opportunities. In this position, he helped drive Bayer’s analgesic franchise to #2 in the category through innovative claims and NDA approvals. He also drove the NDA development, approval and launch of Aleve-D® Sinus & Cold direct to OTC.

Randy began his career at Bristol-Myers Products, the consumer division of BMS, where he held roles of increasing responsibility within R&D. His accomplishments include ideating and patenting Excedrin Migraine, designing its clinical development program and supporting NDA submission and approval as the first OTC migraine product. He also supported submission and approval of Vagistat-1, now marketed as Monistat® 1.

Randy has Ph.D. in Respiratory Physiology from the Temple University School of Medicine and completed a Postdoctoral Fellowship in Neuropharmacology at Hahnemann University School of Medicine.